fb-pixel Skip to main content

Moderna wants to add doses to its vials to speed COVID-19 vaccinations

As Moderna approaches its daily production benchmark of 1 million doses, the company’s president, Stephen Hoge, wants to increase the contents of each vial to 15 doses to relieve “one of the manufacturing bottlenecks.”

Moderna says vaccine study in adolescents has picked up speed

The Cambridge company hopes to have results by the summer.

Selling stock like clockwork, Moderna’s top doctor gets $1 million richer every week

As the world awaits results from Moderna’s pivotal COVID-19 vaccine study, Chief Medical Officer Tal Zaks has been selling his existing stock like clockwork, earning him over $50 million since the dawn of the pandemic.

Stock price of German COVID-19 vaccine maker with US headquarters in Boston closes up nearly 250% in its debut

'This is kind of beyond expectations,' says CureVac's chief financial officer.

Another potential COVID-19 vaccine with Boston ties to enter clinical trials
CureVac, a German firm with about 20 employees here, says it has permission to start testing in people.

For some biotech employees in the age of COVID-19, the workday starts at the bathroom sink
Tango Therapeutics in Cambridge tests workers' gargled samples, then e-mails the results later that day.

Latest Headlines in Biotech